152 related articles for article (PubMed ID: 25383653)
1. Peritoneal tumor carcinomatosis: pharmacological targeting with hyaluronan-based bioconjugates overcomes therapeutic indications of current drugs.
Montagner IM; Merlo A; Zuccolotto G; Renier D; Campisi M; Pasut G; Zanovello P; Rosato A
PLoS One; 2014; 9(11):e112240. PubMed ID: 25383653
[TBL] [Abstract][Full Text] [Related]
2. CD44-targeting for antitumor drug delivery: a new SN-38-hyaluronan bioconjugate for locoregional treatment of peritoneal carcinomatosis.
Serafino A; Zonfrillo M; Andreola F; Psaila R; Mercuri L; Moroni N; Renier D; Campisi M; Secchieri C; Pierimarchi P
Curr Cancer Drug Targets; 2011 Jun; 11(5):572-85. PubMed ID: 21486216
[TBL] [Abstract][Full Text] [Related]
3. Docetaxel load biodegradable porous microspheres for the treatment of colorectal peritoneal carcinomatosis.
Fan R; Wang Y; Han B; Luo Y; Zhou L; Peng X; Wu M; Zheng Y; Guo G
Int J Biol Macromol; 2014 Aug; 69():100-7. PubMed ID: 24854212
[TBL] [Abstract][Full Text] [Related]
4. Drug conjugation to hyaluronan widens therapeutic indications for ovarian cancer.
Montagner IM; Merlo A; Carpanese D; Zuccolotto G; Renier D; Campisi M; Pasut G; Zanovello P; Rosato A
Oncoscience; 2015; 2(4):373-81. PubMed ID: 26097871
[TBL] [Abstract][Full Text] [Related]
5. Intraperitoneal administration of novel doxorubicin loaded polymeric delivery systems against peritoneal carcinomatosis: experimental study in a murine model of ovarian cancer.
Colombo PE; Boustta M; Poujol S; Jarlier M; Bressolle F; Teulon I; Ladjemi MZ; Pinguet F; Rouanet P; Vert M
Gynecol Oncol; 2011 Sep; 122(3):632-40. PubMed ID: 21665252
[TBL] [Abstract][Full Text] [Related]
6. Paclitaxel-hyaluronan hydrosoluble bioconjugate: mechanism of action in human bladder cancer cell lines.
Montagner IM; Banzato A; Zuccolotto G; Renier D; Campisi M; Bassi P; Zanovello P; Rosato A
Urol Oncol; 2013 Oct; 31(7):1261-9. PubMed ID: 22341413
[TBL] [Abstract][Full Text] [Related]
7. Hyaluronic acid-paclitaxel: effects of intraperitoneal administration against CD44(+) human ovarian cancer xenografts.
De Stefano I; Battaglia A; Zannoni GF; Prisco MG; Fattorossi A; Travaglia D; Baroni S; Renier D; Scambia G; Ferlini C; Gallo D
Cancer Chemother Pharmacol; 2011 Jul; 68(1):107-16. PubMed ID: 20848284
[TBL] [Abstract][Full Text] [Related]
8. CD44-targeted microparticles for delivery of cisplatin to peritoneal metastases.
Li SD; Howell SB
Mol Pharm; 2010 Feb; 7(1):280-90. PubMed ID: 19994852
[TBL] [Abstract][Full Text] [Related]
9. A paclitaxel-hyaluronan bioconjugate targeting ovarian cancer affords a potent in vivo therapeutic activity.
Banzato A; Bobisse S; Rondina M; Renier D; Bettella F; Esposito G; Quintieri L; Meléndez-Alafort L; Mazzi U; Zanovello P; Rosato A
Clin Cancer Res; 2008 Jun; 14(11):3598-606. PubMed ID: 18519794
[TBL] [Abstract][Full Text] [Related]
10. Comparative study of the antitumor activity of Nab-paclitaxel and intraperitoneal solvent-based paclitaxel regarding peritoneal metastasis in gastric cancer.
Kinoshita J; Fushida S; Tsukada T; Oyama K; Watanabe T; Shoji M; Okamoto K; Nakanuma S; Sakai S; Makino I; Furukawa H; Hayashi H; Nakamura K; Inokuchi M; Nakagawara H; Miyashita T; Tajima H; Takamura H; Ninomiya I; Fujimura T; Masakazu Y; Hirakawa K; Ohta T
Oncol Rep; 2014 Jul; 32(1):89-96. PubMed ID: 24859429
[TBL] [Abstract][Full Text] [Related]
11. Reversibly crosslinked hyaluronic acid nanoparticles for active targeting and intelligent delivery of doxorubicin to drug resistant CD44+ human breast tumor xenografts.
Zhong Y; Zhang J; Cheng R; Deng C; Meng F; Xie F; Zhong Z
J Control Release; 2015 May; 205():144-54. PubMed ID: 25596560
[TBL] [Abstract][Full Text] [Related]
12. Advances and advantages of nanomedicine in the pharmacological targeting of hyaluronan-CD44 interactions and signaling in cancer.
Skandalis SS; Gialeli C; Theocharis AD; Karamanos NK
Adv Cancer Res; 2014; 123():277-317. PubMed ID: 25081534
[TBL] [Abstract][Full Text] [Related]
13. In situ cross-linkable high molecular weight hyaluronan-bisphosphonate conjugate for localized delivery and cell-specific targeting: a hydrogel linked prodrug approach.
Varghese OP; Sun W; Hilborn J; Ossipov DA
J Am Chem Soc; 2009 Jul; 131(25):8781-3. PubMed ID: 19499915
[TBL] [Abstract][Full Text] [Related]
14. Efficient inhibition of colorectal peritoneal carcinomatosis by drug loaded micelles in thermosensitive hydrogel composites.
Gong C; Wang C; Wang Y; Wu Q; Zhang D; Luo F; Qian Z
Nanoscale; 2012 May; 4(10):3095-104. PubMed ID: 22535210
[TBL] [Abstract][Full Text] [Related]
15. Hyaluronan as drug carrier. The in vitro efficacy and selectivity of Hyaluronan-Doxorubicin complexes to affect the viability of overexpressing CD44 receptor cells.
Battistini FD; Flores-Martin J; Olivera ME; Genti-Raimondi S; Manzo RH
Eur J Pharm Sci; 2014 Dec; 65():122-9. PubMed ID: 25242358
[TBL] [Abstract][Full Text] [Related]
16. Selective killing of breast cancer cells expressing activated CD44 using CD44 ligand-coated nanoparticles in vitro and in vivo.
Yang C; He Y; Zhang H; Liu Y; Wang W; Du Y; Gao F
Oncotarget; 2015 Jun; 6(17):15283-96. PubMed ID: 25909172
[TBL] [Abstract][Full Text] [Related]
17. Smart nanocarrier based on PEGylated hyaluronic acid for cancer therapy.
Choi KY; Yoon HY; Kim JH; Bae SM; Park RW; Kang YM; Kim IS; Kwon IC; Choi K; Jeong SY; Kim K; Park JH
ACS Nano; 2011 Nov; 5(11):8591-9. PubMed ID: 21967065
[TBL] [Abstract][Full Text] [Related]
18. Intraperitoneal delivery of platinum with in-situ crosslinkable hyaluronic acid gel for local therapy of ovarian cancer.
Cho EJ; Sun B; Doh KO; Wilson EM; Torregrosa-Allen S; Elzey BD; Yeo Y
Biomaterials; 2015 Jan; 37():312-9. PubMed ID: 25453960
[TBL] [Abstract][Full Text] [Related]
19. Dual targeting folate-conjugated hyaluronic acid polymeric micelles for paclitaxel delivery.
Liu Y; Sun J; Cao W; Yang J; Lian H; Li X; Sun Y; Wang Y; Wang S; He Z
Int J Pharm; 2011 Dec; 421(1):160-9. PubMed ID: 21945183
[TBL] [Abstract][Full Text] [Related]
20. Antitumor activity of albendazole against the human colorectal cancer cell line HT-29: in vitro and in a xenograft model of peritoneal carcinomatosis.
Pourgholami MH; Akhter J; Wang L; Lu Y; Morris DL
Cancer Chemother Pharmacol; 2005 May; 55(5):425-32. PubMed ID: 15565325
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
